Other Clinical Trial - Intergroup Trial for Children or Adolescents With

Updated 05/14/2024

Status Active, not recruiting

Clinical Trial Summary

Phase II trial to determine the efficacy of Dose Adjusted-EPOCH-Rituximab regimen in children and adolescent with primary mediastinal large B cell lymphoma in terms of event free survival.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Lymphoma
Lymphoma, B-Cell
Primary Mediastinal Large B Cell Lymphoma

Clinical Trial Details

NCT number	NCT01516567
Study type	Interventional
Source	Gustave Roussy, Cancer Campus, Grand Paris
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	April 1, 2012
Completion date	December 2021

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT04545762` - Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma	Phase 1
	Recruiting	`NCT05934448` - Pembro Plus CAR T-cell Therapy in R/R in PMBCL	Phase 2
	Recruiting	`NCT05326243` - Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma	Phase 1/Phase 2
	Completed	`NCT04323657` - TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia	Phase 1/Phase 2
	Terminated	`NCT04844086` - RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies	Phase 1
	Active, not recruiting	`NCT04067414` - Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma	Phase 1
	Not yet recruiting	`NCT06412068` - A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment	Phase 2
	Active, not recruiting	`NCT04464200` - 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers	Phase 1
	Recruiting	`NCT05653271` - ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies	Phase 1
	Enrolling by invitation	`NCT04488354` - Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T	Phase 1
	Recruiting	`NCT04705129` - Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL	Phase 2
	Recruiting	`NCT05377307` - Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy
	Withdrawn	`NCT04503538` - Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity	N/A
	Active, not recruiting	`NCT04542824` - Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL	Phase 1/Phase 2
	Active, not recruiting	`NCT04450069` - CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies	Phase 1
	Recruiting	`NCT05544019` - Study of SGR-1505 in Mature B-Cell Neoplasms	Phase 1